+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alpha- Antitrypsin Deficiency (AATD) - Epidemiology Forecast - 2028

  • ID: 4330786
  • Report
  • 100 pages
  • DelveInsight
1 of 2
‘Alpha - Antitrypsin Deficiency (AATD) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom).

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017-2028

Alpha - Antitrypsin Deficiency (AATD) - Disease Understanding and Treatment Algorithm

The Alpha - Antitrypsin Deficiency (AATD) market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for AATD in the US and Europe.

Alpha - Antitrypsin Deficiency (AATD) Epidemiology

The AATD epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 6 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented into two parts: Population at the risk of developing AATD on the basis of allele [PiSS, PiSZ, PiZZ) and Prevalent cases of AATD in 6 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom)]. As AATD is quite rare in Japan, the report features the diagnosed population of AATD in Japan.

According to the publisher, the prevalent cases of AATD was 235,500 in 2017 in 6MM and, is expected to increase during the study period i.e., 2017-2028. Among 6MM, United States account for highest prevalent cases of AATD with almost 100,000 prevalent cases in 2017. Among the EU5 countries, Germany has the highest prevalent population of AATD with, followed by United Kingdom, which has prevalent population of 27,930 in 2017.

Other than these patients are also segmented based gender and comorbidities associated with Alpha Antitrypsin Deficiency. According to the researcher's analysis, in United States there were 2700 liver disease cases associated with AATD in year 2017.

Alpha - Antitrypsin Deficiency (AATD) Report Insights

The report covers detailed overview of AATD explaining its causes, symptoms, pathophysiology, diagnosis and treatment patterns.

The report provides the insight about the historical and forecasted patient pool for 6 major markets covering the United States & EU5 (Germany, Spain, France, Italy, UK)
  • Patient Population in various epidemiological segments
  • Population at risk of AATD
  • Prevalent Population of AATD
  • Diagnosed Prevalence of AATD
  • Gender Specific case of AATD
  • Comorbidities associated with AATD
  • Therapeutic Approaches
Alpha - Antitrypsin Deficiency (AATD) Report Key Strengths
  • 10 Year Forecast
  • 6MM Coverage
  • Epidemiology Segmentation
Alpha - Antitrypsin Deficiency (AATD) Report Assessment
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
  • Unmet Needs
Key Benefits
  • This report will help to develop Business Strategies by understanding the epidemiology of Alpha - Antitrypsin Deficiency (AATD).
  • The Report helps to recognize the growth opportunities in the 6MM with respect to the patient population
  • Organize research efforts by identifying the best opportunities for AATD disease
  • To understand the future of AATD epidemiology in general population.
Note: Product cover images may vary from those shown
2 of 2
1. Report Introduction

2. Disease Background and Overview: Alpha Antitrypsin Deficiency
2.1. Introduction
2.2. Symptoms
2.3. Etiology
2.4. Risk Factors
2.5. Genetic Inheritance of Alpha Antitrypsin Deficiency
2.6. Pathophysiology
2.7. Complications
2.8. Diagnosis
2.9. Treatment
2.10. Diagnostic Delay

3. Epidemiology and Patient Population
3.1. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM
3.2. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM - By Region
3.3. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM - Distribution (2017)
3.4. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM - Distribution (2028)
3.5. Epidemiology of Alpha-1-Antitrypsin Deficiency- By Country
3.5.1. United States
3.5.1.1. Assumptions and Rationale
3.5.1.2. Population at risk of Alpha Antitrypsin Deficiency in United States
3.5.1.3. Prevalent Population of AATD in The United States
3.5.1.4. Diagnosed Prevalent Population of AATD in The United States
3.5.1.5. Gender- Specific Prevalent Population of AATD in The United States
3.5.1.6. Comorbidities associated with AATD in The United States
3.5.2. EU5
3.5.2.1. Assumptions and Rationale
3.5.2.2. Germany
3.5.2.2.1. Population at risk of Alpha Antitrypsin Deficiency in Germany
3.5.2.2.2. Prevalent Population of Alpha Antitrypsin Deficiency in Germany
3.5.2.2.3. Diagnosed Prevalent Population of AATD in Germany
3.5.2.2.4. Gender- Specific Prevalent Population of AATD in Germany
3.5.2.2.5. Comorbidities associated with AATD in Germany
3.5.2.3. France
3.5.2.3.1. Population at risk of Alpha Antitrypsin Deficiency in France
3.5.2.3.2. Prevalent Population of Alpha Antitrypsin Deficiency in France
3.5.2.3.3. Diagnosed Prevalent Population of AATD in France
3.5.2.3.4. Gender- Specific Prevalent Population of AATD in France
3.5.2.3.5. Comorbidities associated with AATD in France
3.5.2.4. Italy
3.5.2.4.1. Population at risk of Alpha Antitrypsin Deficiency in Italy
3.5.2.4.2. Prevalent Population of Alpha Antitrypsin Deficiency in Italy
3.5.2.4.3. Diagnosed Prevalent Population of AATD in Italy
3.5.2.4.4. Gender- Specific Prevalent Population of AATD in Italy
3.5.2.4.5. Comorbidities associated with AATD in Italy
3.5.2.5. Spain
3.5.2.5.1. Population at risk of Alpha Antitrypsin Deficiency in Spain
3.5.2.5.2. Prevalent Population of Alpha Antitrypsin Deficiency in Spain
3.5.2.5.3. Diagnosed Prevalent Population of AATD in Spain
3.5.2.5.4. Gender- Specific Prevalent Population of AATD in Spain
3.5.2.5.5. Comorbidities associated with AATD in Spain
3.5.2.6. United Kingdom
3.5.2.6.1. Population at risk of Alpha Antitrypsin Deficiency in The UK
3.5.2.6.2. Prevalent Population of Alpha Antitrypsin Deficiency in The UK
3.5.2.6.3. Diagnosed Prevalent Population of AATD in The UK
3.5.2.6.4. Gender- Specific Prevalent Population of AATD in The UK
3.5.2.6.5. Comorbidities associated with AATD in The UK
3.5.3. Japan
3.5.3.1. Diagnosed Population of Alpha Antitrypsin Deficiency in Japan
To be continued in the report

4. Treatment Algorithm
4.1. Management of Alpha-Antitrypsin (AAT) Deficiency with Lung Disease
4.2. Management of Alpha-Antitrypsin (AAT) Deficiency with Liver Disease

5. Unmet Needs

6. Grifols Initiatives towards Alpha Anti-trypsin deficiency

7. USFDA Initiatives for patients with Alpha-1 Antitrypsin Deficiency (AATD)

8. Appendix

9. Report Methodology
9.1. Sources Used

10. Consulting Services

11. Disclaimer

12. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll